Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 288
---
 activities of which the IIA participates by way of grants. According to the funding terms, royalties between   
 3% and 4.5% are payable on sales of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar   
 and bearing Term SOFR interest rate. In the case of failure of a funded research and development activity, the Company is not obligated 
 to pay any such royalties to the IIA. As of December 31, 2023, total contingent obligation to IIA is at the amount of $2,635 (including 
 interest at the amount of $291).                                                                                                        |

| 2. | In February 2018, the Company entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Services Agreement” and “Baxter”, respectively), pursuant to which the Company agreed to purchase certain services from the third party in connection with GelrinC. In April 2022, we amended the Baxter Services Agreement to replace Teva Medical (Marketing) Ltd. (“Teva”) as the supplier of Tisseel under the Supply Agreement for GelrinC with Baxter as Teva ceased to distribute Tisseel in the territory of Israel. |

Under the Baxter Services Agreement, Baxter
provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for all such
support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company will receive a Food and Drug
Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market GelrinC in the
United States, the Company shall pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company will
receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within 30
days after receiving such approval. The Company incurred expenses under the Services Agreement of $60 in each of the year ended December
31, 2023 and 2022.

| 3. | In July 2008, the Company entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company agreed to purchase Tisseel VHSD fibrin sealant Kit (the “Tisseel”), from Teva, with Teva being Baxter’s exclusive